Source: International Congress 2016 – Asthma: mechanisms and biomarkers that promote clinical understanding
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Tomoko Tajiri (Kyoto-shi, Japan), Tomoko Tajiri, Hisako Matsumoto, Yasuhiro Gon, Reiko Ito, Shu Hashimoto, Kenji Izuhara, Junya Ono, Shoichiro Ohta, Isao Ito, Tsuyoshi Oguma, Hideki Inoue, Toshiyuki Iwata, Tadao Nagasaki, Yoshihiro Kanemitsu, Akio Niimi, Michiaki Mishima. Free serum IL-18 levels and responsiveness to omalizumab in patients with severe asthma. Eur Respir J 2016; 48: Suppl. 60, 575

Member's Comments

No comment yet.

Related content which might interest you: Total and free IgE in evolution of severe asthma after omalizumab treatment Source: International Congress 2016 – Asthma management Year: 2016 Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentrations Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015 Assessment of serum magnesium level in patients with bronchial asthma Source: International Congress 2016 – Systemic biomarkers Year: 2016 Correlation between asthma control and serum levels of IL-33 in atopic asthma Source: International Congress 2016 – Laboratory tests and cell biology in allergy and immunology Year: 2016 Asthma control, symptoms and exacerbations across treatment levels in patients with asthma Source: Annual Congress 2013 –Management of respiratory diseases in primary care Year: 2013 Elevated blood eosinophil is a risk factor for future exacerbations in asthmatic children Source: International Congress 2014 – Paediatric asthma: markers and molecules Year: 2014 Variability of total serum IgE in moderate-to-severe asthmatic patients Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 Levels of cytokines, sCD31 and expression of CD38 in patients with bronchial asthma of various severity out of a disease exacerbation Source: International Congress 2014 – Biomarkers of asthma and clinical immunology Year: 2014 Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Effect of baseline eosinophil count on response to CYT003-QbG10 in patients with persistent allergic asthma Source: Annual Congress 2013 –Studies of asthma in man Year: 2013 Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients Source: International Congress 2015 – Asthma and lung immunology Year: 2015 Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study Source: International Congress 2016 – Asthma points to ponder Year: 2016 Effect of tralokinumab on serum periostin and IgE levels in uncontrolled severe asthma Source: International Congress 2015 – Advances in the future treatment of severe asthma Year: 2015 Serum IL-10 and IL-17 are not related to the efficacy of allergen specific immunotherapy in asthma Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 Sputum eosinophilia in severe allergic asthma is not a reliable marker of omalizumab treatment Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 Dupilumab reduces severe exacerbations in periostin-high and periostin-low asthma patients Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016 APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 Experience with omalizumab in patients with moderate and severe asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Clinical effectiveness of anti-IgE therapy in allergic severe asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Bronchial hyperactivity in perimenstrual asthma is higher than in non-PMA asthmatics and correlates with sputum levels of eotaxin and IL-4 Source: International Congress 2014 – Biomarkers of asthma and clinical immunology Year: 2014